

Special Issue

Current Advances in Clinical Genomics and Treatment of Urothelial Carcinoma

Message from the Guest Editor

Immense progress in large-scale genomics projects is transforming the therapeutic landscape of various cancers. Urothelial carcinoma is a common, potentially lethal malignancy, particularly in the advanced stage. Immune checkpoint inhibitors, antibody drug conjugates, and novel targeted agents have become part of the treatment armamentarium for urothelial carcinoma. An important challenge for clinicians is how to best utilize genomic approaches to predict treatment responses and identify patients who can derive a preferential benefit from these therapeutic options. This Special Issue aims at providing an update on recent advances in the molecular landscape of UC and how genomic alterations in key signaling pathways might serve in biomarker development, drug development, and prediction of patient outcomes. Dr. Panagiotis J. Vlachostergios

Guest Editor

Dr. Panagiotis Vlachostergios

Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA

Deadline for manuscript submissions

closed (30 June 2022)



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



mdpi.com/si/82662

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentoncol](https://mdpi.com/journal/currentoncol)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



[mdpi.com/journal/
currentcol](https://mdpi.com/journal/currentcol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)